Q-omics provides the consensus-scored MIR8083 profile across patient tissues and cancer cell-line models. MIR8083 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, MIR8083 is differentially expressed in 5, with the highest sampling consensus in KICH. Additionally, MIR8083 RNA expression shows 8,416 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight BLCA, KICH, and THYM as cancer lineages where MIR8083 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR8083 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR8083 survival associations across molecular data types. MIR8083 RNA expression shows survival associations in the most cancer types (20). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR8083 RNA expression–survival associations across cancer types. High MIR8083 expression shows unfavorable associations in BLCA, BRCA, CESC and UCEC, but favorable associations in ESCA and LUAD. The BLCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .003). Together, the overview and detailed table identify BLCA as the clearest survival context for MIR8083 RNA expression.
This table summarizes MIR8083 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for MIR8083. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR8083 shows lower tumor expression in KICH, BRCA, LUSC, LUAD and UCEC. The KICH box plot shows higher MIR8083 RNA expression in normal versus tumor tissue (log2 FC = −0.643, t-test p < 0.001).
This table shows molecular features associated with MIR8083 in patient tissues and cancer cell lines. In patient samples, MIR8083 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
